OrbitalHub

For a patient whose genome has just been sequenced, the diagnostic question usually is not whether a strange variant exists. There will be dozens. The question is which one of them is making them sick. On 8 September 2026, Google DeepMind released AlphaGenome Atlas, a one-petabyte, nine-billion-row table that aims to make that triage a single look-up instead of a multi-month investigation. It is the largest precomputed biological dataset the company has ever released, more than thirty times the size of the AlphaFold Protein Structure Database at launch (DeepMind, 2026), and it covers the 98 percent of the human genome that does not code for proteins at all.

What the team has done is straightforward to describe and almost absurd in its engineering ambition: take the AlphaGenome sequence-to-function model they published in Nature in January 2026, run it across every possible single-letter substitution at every one of the roughly three billion positions of the human reference genome, store the predictions, and serve them on the open web. Every variant. In advance. With feature attributions attached. With a single composite score, the AlphaGenome Variant Impact (AVI), that collapses the predictions into a number clinical researchers can rank variants by. The bottleneck in human genetics, in other words, has just moved.

To see why this matters, it helps to remember where the field stood a decade ago. In the early 2010s, the human genome was widely described as 98 percent “junk DNA.” That framing did not survive contact with ENCODE, the Roadmap Epigenomics Project, GTEx, or any of the consortium-scale projects that mapped chromatin accessibility, transcription factor binding, histone modifications, and three-dimensional genome contacts across hundreds of cell types. By the early 2020s the consensus was unambiguous: most of the variants statistically associated with common traits and many rare diseases live outside coding exons, in regulatory regions whose effect on the organism can only be inferred by reading the sequence around them and computing what those regions should be doing (Nature, Avsec et al., 2026). The Human Cell Atlas, the 4D Nucleome, FANTOM5 — they produced the data. Predicting the effect of any given mutation on gene expression, splicing, or chromatin, on demand, was the missing piece.

DeepMind’s path to Atlas runs through three increasingly ambitious releases. AlphaFold, in 2020, solved the decades-old protein folding problem and earned Demis Hassabis and John Jumper a share of the 2024 Nobel Prize in Chemistry (Nobel Foundation, 2024). AlphaMissense, in 2023, classified all 71 million possible missense variants in the protein-coding part of the genome as likely benign or pathogenic. Both tools covered only the 2 percent that codes for proteins. AlphaGenome, first released for non-commercial research in June 2025 and described in Nature in January 2026, covers the other 98 percent. Atlas is the precomputed, freely searchable version of that model (DeepMind, 2026; Avsec et al., Nature, 2026).

The early-access users announced alongside the release illustrate what shifts when the bottleneck moves. Laura Covill and Anne O’Donnell-Luria at the Broad Institute used the AVI score to reprioritise a variant in DNM1, a gene strongly linked to epileptic encephalopathy, that had been overlooked in earlier analyses; AlphaGenome predicted an abnormal splice site extending the resulting protein, a mechanism subsequently confirmed by laboratory experiments (DeepMind, 2026). Gareth Hawkes, an MRC fellow at the University of Exeter, ran the Atlas over whole-genome data from more than 54,000 UK Biobank participants and reported 22 percent more non-coding genetic associations than prior pipelines surfaced, including regulatory variants affecting PLA2G7 and EGLN1 and nineteen new regions linked to body mass index. At the Stowers Institute, Julia Zeitlinger and Melanie Weilert used the database to separate transcription factors by their regulatory effects on chromatin, a problem that has resisted biochemical characterisation for two decades.

The architecture behind those results is what makes the engineering tractable. AlphaGenome uses a U-Net-style neural network: an encoder that compresses one million base pairs of input DNA into a dense representation, a stack of transformer blocks that pass information between distant regulatory elements across that window, and a decoder that reconstructs base-pair-resolution predictions across eleven molecular modalities — gene expression, RNA splicing, chromatin accessibility, histone modification, transcription factor binding, three-dimensional contacts, and others — for hundreds of human and mouse cell types (Avsec et al., Nature, 2026). The model was pre-trained on 256 Google TPUv3 chips working in parallel over data from ENCODE, GTEx, the 4D Nucleome, and FANTOM5, and then distilled into a smaller student model that completes the full all-modality, all-cell-type prediction for a single variant in under one second on a single NVIDIA H100 GPU. DeepMind’s genomics lead Žiga Avsec told reporters the team needed an 80-fold speedup over their initial pipeline to make Atlas feasible; they reached it through a combination of model distillation, GPU kernel optimisation, and aggressive elimination of redundant computation (DeepMind, 2026).

The AVI score itself is what lets researchers act on those predictions. It folds the eleven AlphaGenome modalities together with AlphaMissense’s protein-impact estimates and an evolutionary-conservation signal into a single number. On solved rare-disease cases from the GREGoR Consortium, the score placed the known causal variant in the top fifty candidates 29.5 percent of the time; CADD, the most widely used genome-wide variant scoring system in clinical genomics today, managed 12.5 percent on the same benchmark — a 2.4-fold improvement on the metric that matters most to a clinician staring at a patient’s exome (DeepMind, 2026). Each AVI score is paired with feature attributions that say which modality is doing the heavy lifting for any given variant, so a researcher can see not just that a mutation looks bad but why it looks bad.

What changes now is the geometry of the work. Before Atlas, a clinical genomics group that wanted to score a list of candidate variants had to either run a model themselves, rent the compute, or wait on a collaborator who could. After Atlas, they open a browser, type a chromosome coordinate, and read off the score. The cost has collapsed from days of GPU time and a real infrastructure bill to a single API call. The companion AlphaGenome Variant Impact score is freely available through a web portal and API for non-commercial research now, with commercial availability on Google Cloud slated to follow. DeepMind is explicit that the output is not approved for clinical use, and independent reviewers have flagged the obvious limits: many diseases involve multiple interacting variants rather than a single mutation, and some enhancers act over distances longer than the one-million-base-pair window AlphaGenome examines, so their effects fall outside what the model can see (NeoScienceHub, 2026).

The next twenty years of precision medicine will be shaped less by any single sequencing technology than by how quickly reference databases like this one become the substrate that all downstream tools assume exists. AlphaFold did that for structural biology between 2021 and 2025: a problem that used to take a graduate student a year collapsed into something a high schooler could look up. AlphaGenome Atlas has now attempted the same move for the rest of the genome. Whether it actually accelerates diagnoses and mechanism discovery at scale will not be settled in the press release; it will be settled in the next five years of clinical genetics journals, where the question of how often a researcher who never had to run the model themselves first ends up reading the right page of the answer.